» Articles » PMID: 32782579

Downregulation of the Let-7 Family of MicroRNAs May Promote Insulin Receptor/insulin-like Growth Factor Signalling Pathways in Pancreatic Ductal Adenocarcinoma

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Aug 13
PMID 32782579
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type characterized by dysregulated cell signalling pathways and resistance to treatment. The insulin-like growth factor (IGF) signalling pathway has been identified to have a role in tumour progression and therapy resistance. However, its regulatory roles in PDAC have remained to be fully elucidated. In the present study, dysregulated microRNAs (miRNAs) in PDAC were explored with a focus on those that may be involved in regulating the insulin/IGF signalling pathway. A total of 208 patients were recruited, comprising 112 patients with PDAC, 50 patients with chronic pancreatitis (CP) and 46 subjects as a control group (CG). miRNA-specific quantitative PCR assays were used to measure 300 candidate miRNAs. The Student's t-test was applied to compare miRNA regulation between cancer patients and controls with a false discovery rate correction using Bonferroni-type comparison procedures. The DIANA-mirPath v.3 tool and HMDD v3.0 were used to identify miRNA-mRNA interactions within specific pathways. In patients with PDAC, 42 miRNAs were significantly upregulated and 42 were downregulated compared to the CG (P<0.01). In the PDAC vs. CP analysis, 16 significantly (P<0.01) upregulated and 16 downregulated miRNAs were identified. Of note, members of the let-7 family of miRNAs were downregulated and were indicated to target several components of the insulin receptor (INSR)/IGF pathway, including receptors and binding proteins, for upregulation and thus, may enable the activation of the pathway. Downregulation of the let-7 family may help promote the INSR/IGF pathway in PDAC. It may thus be an effective target for the development of INSR/IGF pathway-specific treatment strategies.

Citing Articles

Non-coding RNAs as therapeutic targets in cancer and its clinical application.

Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y J Pharm Anal. 2024; 14(7):100947.

PMID: 39149142 PMC: 11325817. DOI: 10.1016/j.jpha.2024.02.001.


Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.

Pal A, Ojha A, Ju J Int J Mol Sci. 2023; 24(24).

PMID: 38139352 PMC: 10744132. DOI: 10.3390/ijms242417523.


Identification of MicroRNAs Associated with Prediabetic Status in Obese Women.

Kovac L, Speckmann T, Jahnert M, Gottmann P, Fritsche L, Haring H Int J Mol Sci. 2023; 24(21).

PMID: 37958657 PMC: 10648886. DOI: 10.3390/ijms242115673.


Microbiome and MicroRNA or Long Non-Coding RNA-Two Modern Approaches to Understanding Pancreatic Ductal Adenocarcinoma.

Izdebska W, Daniluk J, Niklinski J J Clin Med. 2023; 12(17).

PMID: 37685710 PMC: 10488817. DOI: 10.3390/jcm12175643.


Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma.

Liu T, Chen Z, Chen W, Evans R, Xu J, Reeves M Precis Clin Med. 2023; 6(1):pbad004.

PMID: 37007745 PMC: 10052370. DOI: 10.1093/pcmedi/pbad004.


References
1.
Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

2.
LeRoith D, Roberts Jr C . The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195(2):127-37. DOI: 10.1016/s0304-3835(03)00159-9. View

3.
Perkhofer L, Illing A, Gout J, Frappart P, Kleger A . Precision medicine meets the DNA damage response in pancreatic cancer. Oncoscience. 2018; 5(1-2):6-8. PMC: 5854286. DOI: 10.18632/oncoscience.392. View

4.
Kirkegard J, Mortensen F, Cronin-Fenton D . Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2017; 112(9):1366-1372. DOI: 10.1038/ajg.2017.218. View

5.
Li Y, VandenBoom 2nd T, Kong D, Wang Z, Ali S, Philip P . Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009; 69(16):6704-12. PMC: 2727571. DOI: 10.1158/0008-5472.CAN-09-1298. View